A co-authored paper by NAKAGAMI Yuki Faculty of Data Science and others (Joint research with the Department of Gastroenterology and Oncology, Graduate School of Medicine, Yamaguchi University, and the Oncology Center of Yamaguchi University Hospital) has been published in an international journal. The journal published by MDPI, which currently has a high impact factor in cancer-related research journals (IF: 6.575), is attracting attention.

For more information, please click here.

https://www.mdpi.com/2072-6694/16/14/2522

Information on thesis　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　

Magazine name: Cancers

Thesis title: Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer "Safety and feasibility of preoperative mFOLFIRINOX therapy for elderly pancreatic cancer"

Author: Yoshitaro Shindo¹, Tatsuya Ioka², Yukio Tokumitsu¹, Hiroto Matsui¹, Masao Nakajima¹, Yuta Kimura¹, Yusaku Watanabe¹, Shinobu Tomochika¹, Yuki Nakagami^1,3, Ryouichi Tsunedomi¹, Michihisa Iida¹, Hidenori Takahashi¹, and Hiroaki Nagano¹

¹Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine

²Department of Oncology Center, Yamaguchi University Hospital

³Department of Data Science, Shimonoseki City University

Overview of Research　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　

Preoperative chemotherapy (Neoadjuvant chemotherapy: NAC) is known to be effective in improving prognosis in patients with resectable and resectable boundary pancreatic cancer (PC). Modified FOLFIRINOX (mFOLFIRINOX) therapy is widely used as a standard therapy, but due to its toxicity, it is not applicable to patients over 75 years old. Elderly patients are also more likely to have complications and have a high risk of adverse events associated with chemotherapy. Therefore, considering the rapid increase in the number of elderly patients, it is necessary to verify whether NAC is feasible for both non-elderly and elderly patients.

In this study, we examined the safety and feasibility of preoperative mFOLFIRINOX therapy for elderly pancreatic cancer using advanced statistical modeling and survival time analysis. As a result, it was found that perioperative and postoperative outcomes in older patients who received preoperative mFOLFIRINOX were similar compared with non-elderly patients. It was suggested that preoperative mFOLFIRINOX for elderly pancreatic cancer is a feasible option.

[Publishing date: 2024.7.22]

[Contact]
Public university corporation Shimonoseki City University
Corporate Planning Department Public Relations and Branding Strategy Division
TEL. 083-253-8967